State Street Corp Takes $777,000 Position in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

State Street Corp acquired a new stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 48,592 shares of the company’s stock, valued at approximately $777,000.

A number of other large investors have also recently bought and sold shares of the business. TD Asset Management Inc lifted its position in shares of Centessa Pharmaceuticals by 40.5% in the second quarter. TD Asset Management Inc now owns 321,168 shares of the company’s stock worth $2,900,000 after buying an additional 92,524 shares during the last quarter. American Century Companies Inc. lifted its holdings in Centessa Pharmaceuticals by 1.3% in the 2nd quarter. American Century Companies Inc. now owns 935,151 shares of the company’s stock worth $8,444,000 after purchasing an additional 12,031 shares during the last quarter. XTX Topco Ltd bought a new stake in Centessa Pharmaceuticals during the second quarter worth approximately $148,000. Farallon Capital Management LLC boosted its position in Centessa Pharmaceuticals by 438.0% during the second quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company’s stock worth $18,024,000 after purchasing an additional 1,625,000 shares during the period. Finally, First Light Asset Management LLC grew its holdings in Centessa Pharmaceuticals by 59.2% during the second quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock valued at $43,168,000 after purchasing an additional 1,778,515 shares during the last quarter. 82.01% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, insider Gregory M. Weinhoff sold 11,742 shares of the stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $15.38, for a total value of $180,591.96. Following the completion of the transaction, the insider now owns 183,266 shares of the company’s stock, valued at $2,818,631.08. This represents a 6.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Saurabh Saha sold 2,592 shares of the firm’s stock in a transaction dated Wednesday, October 23rd. The stock was sold at an average price of $15.32, for a total transaction of $39,709.44. Following the transaction, the chief executive officer now owns 630,661 shares of the company’s stock, valued at approximately $9,661,726.52. This represents a 0.41 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 368,023 shares of company stock valued at $6,335,574 over the last ninety days. 11.59% of the stock is owned by company insiders.

Centessa Pharmaceuticals Stock Performance

NASDAQ:CNTA opened at $17.50 on Friday. The firm’s 50-day moving average is $16.84 and its 200-day moving average is $14.06. The company has a market cap of $2.31 billion, a price-to-earnings ratio of -11.44 and a beta of 1.52. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. Centessa Pharmaceuticals plc has a 52-week low of $6.65 and a 52-week high of $18.97.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.05. Equities research analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have recently weighed in on CNTA. Morgan Stanley upgraded shares of Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $11.00 to $26.00 in a research note on Thursday, September 19th. Jefferies Financial Group upped their price target on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. B. Riley began coverage on Centessa Pharmaceuticals in a research report on Thursday, September 19th. They issued a “buy” rating and a $33.00 price target on the stock. Guggenheim boosted their price objective on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Finally, BMO Capital Markets raised their target price on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a report on Monday, September 16th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Centessa Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.